AU
AUTL
Autolus Therapeutics plc
$1.56
0.00%
$415.2M
No data for this timeframe.
Vol
Market Cap$415.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders32 funds
Inst. Value$59.4M
Inst. Activity2 buys / 6 sells
SEC Reports5
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. X0·CIK 0001730463·Prev Close $1.56
Recent Activity
Jun 11, 2026
SEC
A mixed institutional cluster in AUTL for Q3 2025 shows quant funds (Citadel, RenTech) and passive managers (Morgan Stan
INST-CLUSTER — Impact 6/10
Jun 9, 2026
SEC
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656
8-K — Impact 7/10
May 14, 2026
SEC
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M, achieving its firs
8-K — Impact 6/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
2,299,499 shares ($3.2M)
Inst.
BlackRock, Inc. — TRIM
1,480,732 shares ($2.0M)
Jun 12, 2026
Press
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recog
Impact 3/10
Jun 12, 2026
contract
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics was awarded Prix Galien UK 2026 Best Biotechnology Product
May 21, 2026
Press
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59
Impact 4/10
Price Targets
$8.71
+458.4% upside
Strong Buy
Current $1.56
Low $5.00
Median $10.00
High $11.00
9 analysts
$5.00
$11.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 9, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Needham | REITERATE | Buy → Buy |
| Feb 17, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▲ +9.8% | $-0.31 — $-0.18 | -28% YoY | 7 |
| Next Q | $-0.21 ▲ +10.3% | $-0.27 — $-0.17 | 29% YoY | 7 |
| Current FY | $-0.90 ▲ +5.9% | $-1.24 — $-0.56 | 17% YoY | 9 |
| Next FY | $-0.63 ▲ +10.8% | $-0.97 — $-0.42 | 30% YoY | 9 |
Latest Reports
NEUTRAL
Press
3/10
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recog
Jun 12, 2026
BEARISH
INST-CLUSTER
6/10
A mixed institutional cluster in AUTL for Q3 2025 shows quant funds (Citadel, RenTech) and passive managers (Morgan Stan
Jun 11, 2026
BEARISH
8-K
7/10
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656
Jun 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Blackstone Inc. | $28.3M | EXIT |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.1M | DOUBLED |
| BNP Paribas Asset Management | $4.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.2M | TRIM |
| BANK OF AMERICA CORP | $2.5M | DOUBLED |
32 institutional holders with $59.4M total value (43,809,166 shares) as of 2026-Q1. Top holders: Blackstone, SCHRODER, BNP. Net selling activity: 6 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Blackstone Inc. | 20,485,611 | $28.3M | 47.6% | EXIT -100.0% |
| 2 | SCHRODER INVESTMENT MANAGEMENT GROUP | 9,489,345 | $12.1M | 20.3% | DOUBLED +133.7% |
| 3 | BNP Paribas Asset Management Holding S.A. | 3,361,156 | $4.6M | 7.8% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 2,299,499 | $3.2M | 5.3% | TRIM -26.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 1,844,671 | $2.5M | 4.3% | DOUBLED +108.1% |
| 6 | BlackRock, Inc. | 1,480,732 | $2.0M | 3.4% | TRIM -59.8% |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 971,691 | $1.3M | 2.3% | — |
| 8 | MORGAN STANLEY | 941,823 | $1.3M | 2.2% | TRIM -32.6% |
| 9 | Marex Group plc | 542,857 | $749.1K | 1.3% | — |
| 10 | CITADEL ADVISORS LLC | 459,404 | $634.0K | 1.1% | DOUBLED +501.8% |
| 11 | Point72 Asset Management, L.P. | 426,983 | $589.2K | 1.0% | ADD +39.8% |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 399,143 | $550.8K | 0.9% | — |
| 13 | WELLS FARGO & COMPANY/MN | 207,856 | $286.8K | 0.5% | — |
| 14 | Erste Asset Management GmbH | 195,000 | $247.7K | 0.4% | — |
| 15 | CITADEL ADVISORS LLC | 126,400 | $174.4K | 0.3% | DOUBLED +501.8% |
| 16 | GOLDMAN SACHS GROUP INC | 116,413 | $160.7K | 0.3% | — |
| 17 | STATE STREET CORP | 83,540 | $115.3K | 0.2% | TRIM -73.4% |
| 18 | Invesco Ltd. | 53,153 | $73.4K | 0.1% | ADD +35.7% |
| 19 | TUDOR INVESTMENT CORP ET AL | 46,213 | $63.8K | 0.1% | NEAR_EXIT -83.6% |
| 20 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 45,749 | $63.1K | 0.1% | ADD +29.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,105,404 | 2,299,499 | -26.0% | $3.2M | 2026-Q1 |
| BlackRock, Inc. | TRIM | 3,685,825 | 1,480,732 | -59.8% | $2.0M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,397,251 | 941,823 | -32.6% | $1.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 305,359 | 426,983 | +39.8% | $589.2K | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | NEAR_EXIT | 282,113 | 46,213 | -83.6% | $63.8K | 2026-Q1 |
| Rathbones Group PLC | TRIM | 65,000 | 28,050 | -56.8% | $38.7K | 2026-Q1 |
| MARSHALL WACE, LLP | NEAR_EXIT | 270,277 | 26,682 | -90.1% | $36.8K | 2026-Q1 |
| Independent Advisor Alliance | ADD | 13,885 | 22,340 | +60.9% | $30.8K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 4,881,372 | 3,105,404 | -36.4% | $6.2M | 2025-Q4 |
| TUDOR INVESTMENT CORP ET AL | ADD | 206,653 | 282,113 | +36.5% | $561.4K | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 641,952 | 270,277 | -57.9% | $537.9K | 2025-Q4 |
| Invesco Ltd. | ADD | 38,049 | 51,642 | +35.7% | $102.8K | 2025-Q4 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 38,419 | 49,864 | +29.8% | $99.2K | 2025-Q4 |
| RHUMBLINE ADVISERS | ADD | 16,381 | 32,251 | +96.9% | $64.2K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 7,754 | 9,748 | +25.7% | $19.4K | 2025-Q4 |
| Blackstone Inc. | EXIT | 20,485,611 | 0 | -100.0% | $0.00 | 2025-Q4 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 3,608,490 | 8,433,253 | +133.7% | $13.4M | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 1,004,378 | 6,044,243 | +501.8% | $9.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,751,200 | 4,881,372 | +178.7% | $8.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 975,135 | 2,029,593 | +108.1% | $3.3M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 462,606 | 1,213,773 | +162.4% | $2.0M | 2025-Q3 |
| TUDOR INVESTMENT CORP ET AL | ADD | 106,653 | 206,653 | +93.8% | $336.8K | 2025-Q3 |
| Invesco Ltd. | ADD | 29,636 | 38,049 | +28.4% | $62.0K | 2025-Q3 |
| Vanguard Personalized Indexing Management, LLC | TRIM | 30,432 | 20,160 | -33.8% | $32.9K | 2025-Q3 |
| Mariner, LLC | TRIM | 18,947 | 10,322 | -45.5% | $16.8K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 2 mixed, 0 neutral. Avg impact: 6.2/10.
BEARISH
INST-CLUSTER
6/10
A mixed institutional cluster in AUTL for Q3 2025 shows quant funds (Citadel, RenTech) and passive m
Jun 11, 2026
BEARISH
8-K
7/10
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL
Jun 9, 2026
MIXED
8-K
6/10
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M
May 14, 2026
MIXED
PRESS-RELEASE
6/10
Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first
May 14, 2026
BULLISH
8-K
6/10
Autolus Therapeutics held an investor event highlighting real-world data and clinical trial results
Apr 8, 2026
NEUTRAL
3/10
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a presti
Jun 12, 2026
NEUTRAL
4/10
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing o
May 21, 2026
NEUTRAL
3/10
Autolus Therapeutics granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees as in
Apr 21, 2026
NEUTRAL
3/10
Autolus Therapeutics will announce its Q4 and full-year 2025 financial results on March 27, 2026. Th
Mar 16, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.71 mean target
+458.4% upside
Strong Buy (1.10)
$5.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $1.56 |
| Target Low | $5.00 |
| Target Mean | $8.71 |
| Target Median | $10.00 |
| Target High | $11.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.10) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.31 | $-0.18 | -28.0% | +9.8% | 4↑ 0↓ | $0.0B | 44.5% | 7 |
| Next Q 2026-09-30 |
$-0.21 | $-0.27 | $-0.17 | 28.7% | +10.3% | 4↑ 0↓ | $0.0B | 58.0% | 7 |
| Current FY 2026-12-31 |
$-0.90 | $-1.24 | $-0.56 | 16.7% | +5.9% | 5↑ 1↓ | $0.1B | 71.3% | 9 |
| Next FY 2027-12-31 |
$-0.63 | $-0.97 | $-0.42 | 30.0% | +10.8% | 6↑ 1↓ | $0.2B | 49.7% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $-0.232 | +0.001 |
| 30d ago | $-0.255 | +0.025 |
| 60d ago | $-0.251 | +0.021 |
| 90d ago | $-0.240 | +0.010 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 17, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jan 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 29, 2025 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
contract
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics was awarded Prix Galien UK 2026 Best Biotechnology Product
Jun 9, 2026
short_volume
Short Volume: AUTL — 60.7% short (0.5M / 0.7M)
Short: 450,461 | Exempt: 17,214 | TRF Vol: 741,778 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: AUTL — 58.3% short (0.3M / 0.6M)
Short: 334,388 | Exempt: 3,074 | TRF Vol: 573,745 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus will present and host meetings at two upcoming investor conferences.
May 21, 2026
fda
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting.
May 14, 2026
earnings
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.
May 14, 2026
earnings_calendar
AUTL Q1 2026 Earnings Scheduled — 2026-05-14
May 12, 2026
short_volume
Short Volume: AUTL — 57.9% short (0.4M / 0.6M)
Short: 369,935 | Exempt: 400 | TRF Vol: 639,006 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
AUTL Q1 2026 Earnings Scheduled — 2026-05-06
Apr 29, 2026
short_volume
Short Volume: AUTL — 64.0% short (0.5M / 0.8M)
Short: 515,783 | Exempt: 125 | TRF Vol: 806,064 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
activist
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus announces inducement grant awards.
Apr 7, 2026
other
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus will present at upcoming investor conferences.
Apr 1, 2026
Clinical Trial
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Phase Phase 2 — TERMINATED
Mar 27, 2026
earnings
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus announces its operational and financial results for the fourth quarter and full year ended December 31, 2025.
Mar 18, 2026
earnings_calendar
AUTL Q4 2025 Earnings After Market Close — 2026-03-18
Mar 16, 2026
earnings
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus will announce Q4 and FY 2025 financial results on March 27, 2026.